

Module: QScript Learning – High-risk clinical scenarios

Course: PRESCRIBER AND DISPENSER TRAINING

Suggested Citation:

Insight: Centre for AOD Training and Workforce Development. High-risk clinical Scenarios. QScript Learning. Prescriber and dispenser training [Internet]. 2023. Available from: <https://insight.qld.edu.au/training/elearning>.

1. Medicines and Poisons Act 2019, (2019).
2. Queensland Health. Queensland Health Departmental Standard - Monitored Medicines Version 1. 2021.
3. Penington Institute. Australia's annual overdose report 2022. Carlton, VIC: Penington Institute; 2022 [cited 2023 06 Feb]. Available from: https://www.penington.org.au/wp-content/uploads/2022/09/Penington-Institute-AAOR-2022.pdf#msdyntrid=hvzI2f_pjEEiWGU43algZjl1X7pcHpbIH58qj66pXgk.
4. Finley EP, Garcia A, Rosen K, McGeary D, Pugh MJ, Potter JS. Evaluating the impact of prescription drug monitoring program implementation: a scoping review. BMC Health Services Research. 2017;17(420).doi: 10.1186/s12913-017-2354-5
5. Dobbin M, Liew DFL. Real-time prescription monitoring: Helping people at risk of harm. Australian Prescriber. 2020;43(5):164-7.doi: 10.18773/austprescr.2020.050
6. Ogeil RP, Heilbronn C, Lloyd B, Lubman DI. Benefits and challenges to the implementation of real-time prescription monitoring [cited 2021 1 Jan]. Available from: https://medicinetoday.com.au/sites/default/files/cpd/2-MT2015-06SUPPL-PRESCRIPTION_OPIOID_MISUSE_OGEIL.pdf
7. McDougall J. Inquest into the death of William John House, Vanessa Joan White, Jodie Anne Smith; and Daniel Keith Milne. In: Coroners Court of Queensland, editor. 2012/3089, 2012/4575, 2012/2948, 2014/545. Southport: Coroners Court of Queensland; 2018.
8. Toce MS, Michelson KA, Hudgins JD, Hadland SE, Olson KL, Monuteaux MC, et al. Association of Prescription Drug Monitoring Programs with Opioid Prescribing and Overdose in Adolescents and Young Adults. Annals of emergency medicine. 2023.doi:
9. Owston L. The inherited patient on opioids: A challenge for primary care clinicians. Journal of the American Academy of Physician Assistants. 2016;29(10):37-43.doi: 10.1097/01.JAA.0000496955.25829.7f
10. Murphy L, Babaei-Rad R, Buna D, Isaac P, Murphy A, Ng K, et al. Guidance on opioid tapering in the context of chronic pain: Evidence, practical advice and frequently asked questions. Can Pharm J (Ott). 2018;151(2):114-20.doi: 10.1177/1715163518754918
11. Thistlethwaite J, Weeks L. Prescribing new medicines. Australian Journal for General Practitioners. 2018 06/01 [cited 2020 28 Sep]; 47:[327-31 pp.]. Available from: <https://www1.racgp.org.au/ajgp/2018/june/prescribing-new-medicines>.
12. Georgeff M. Digital technologies and chronic disease management. Australian Family Physician. 2014 12/01 [cited 2020 10 Jan]; 43:[842-6 pp.]. Available from: <http://www.racgp.org.au/afp/2014/december/digital-technologies-and-chronic-disease-management/>.
13. Reynolds R, Dennis S, Hasan I, Slewa J, Chen W, Tian D, et al. A systematic review of chronic disease management interventions in primary care. BMC family practice. 2018;19(1):1-13.doi:
14. Pain and Analgesia Expert Group. General principles of chronic pain management [cited 2023 08 Feb]. Available from: https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Pain%20and%20Analgesia&topicfile=general-principles-chronic-pain-management&guidelinename=Pain%20and%20Analgesia§ionId=toc_d1e98#toc_d1e98.
15. Mozafarinia M, Mate KK, Brouillette M-J, Fellows LK, Knäuper B, Mayo NE. An umbrella review of the literature on the effectiveness of goal setting interventions in improving health outcomes in chronic conditions. Disability and Rehabilitation. 2023:1-11.doi:

16. Donnelly C, Leclair L, Hand C, Wener P, Letts L. Occupational therapy services in primary care: a scoping review. *Primary Health Care Research & Development*. 2023;24:e7.doi:
17. Insight Centre for AOD Training and Workforce Development, QScript Learning. Initiating a monitored medicine - Peter & Annette [cited 2021 8 Apr]. Available from: <https://youtu.be/U0sXQmHAHT4>.
18. Insight Centre for AOD Training and Workforce Development. "Using your senses to cope" - sensory tool for clients [cited 2019 7 Sep]. Available from: <https://insight.qld.edu.au/shop/476-using-your-senses-to-cope-sensory-tool-for-clients>.
19. State of Queensland (Queensland Health). Queensland medication-assisted treatment of opioid dependence: Clinical guidelines. Brisbane: Queensland Health; 2018 [cited 2023 Jan 31]. Available from: <https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/clinical-staff/mental-health/guidelines>.
20. NPS MedicineWise. Pain management in patients with a history of opioid dependence: Information for health professionals. Surry Hills2016 [cited 2019 30 June]. Available from: <https://www2.health.vic.gov.au/-/media/health/files/collections/policies-and-guidelines/safe-opioid-use/pain-management-in-patients-with-a-history-of-opioid-dependence---for-health-professionals.pdf>.
21. Arnold RM. Management of acute pain in the patient chronically using opioids. Available from: https://www-uptodate-com.ezp01.library.qut.edu.au/contents/management-of-acute-pain-in-the-patient-chronically-using-opioids?search=Management%20of%20acute%20pain%20in%20the%20patient%20chronically%20using%20opioids&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H2978054.
22. Australian Commission on Safety and Quality in Health Care. Opioid Analgesic Stewardship in Acute Pain, Clinical Care Standard - Acute care edition [cited 2023 13 Feb]. Available from: <https://www.safetyandquality.gov.au/sites/default/files/2022-04/opioid-analgesic-stewardship-in-acute-pain-clinical-care-standard.pdf>.
23. Australian and New Zealand College of Anaesthetists & the Faculty of Pain Medicine. Acute Pain BP. PS41(G) Position statement on acute pain management 20222022.
24. Glare P, Ashton-James C, Han E, Nicholas M. Deprescribing long-term opioid therapy in patients with chronic pain. *Internal medicine journal*. 2020;50(10):1185-91.doi:
25. Matthias MS, Johnson NL, Shields CG, Bair MJ, MacKie P, Huffman M, et al. "I'm Not Gonna Pull the Rug out From Under You": Patient-Provider Communication About Opioid Tapering. *The Journal of Pain*. 2017;18(11):1365-73.doi: 10.1016/j.jpain.2017.06.008
26. Pain and Analgesia Expert Group. Managing acute pain in opioid-tolerant patients [cited 2023 13 Feb]. Available from: https://tqldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Pain%20and%20Analgesia&topicfile=acute-pain-opioid-tolerant-patients&guidelinename=Pain%20and%20Analgesia§ionId=toc_d1e47#toc_d1e47.
27. Insight Centre for AOD Training and Workforce Development, QScript Learning. Managing pain in QOTP registered patients - Dr Geraldine Chew [cited 2021 9 Apr]. Available from: https://youtu.be/bcJ_hwg43OA.
28. Psychotropic Expert Group. Opioids: problem use [cited 2019 30/06]. Available from: https://tqldcdp.tg.org.au/viewTopic?topicfile=alcohol-drug-problems&guidelineName=Psychotropic#toc_d1e424.
29. Pain and Analgesia Expert Group. Alcohol and other Drug Problems [cited 2023 13 Feb]. Available from: https://tqldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Addiction%20Medicine&topicfile=alcohol-drug-problems&guidelinename=Addiction%20Medicine§ionId=toc_d1e424#toc_d1e424.
30. Parsons G. Pain management in patients with a substance use disorder. Available from: https://www.pharmaceutical-journal.com/cpd-and-learning/pain-management-in-patients-with-a-substance-use-disorder/20069490.article?firstPass=false#fn_26.
31. Walsh SL, Middleton LS. Buprenorphine pharmacodynamics and pharmacokinetics. In: Cruciani RA, Knotkova H, editors. *Handbook of Methadone Prescribing and Buprenorphine Therapy*. New York, NY: Springer New York; 2013. p. 163-81.
32. Khanna IK, Pillarisetti S. Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain. *Journal of Pain Research*. 2015;8:859-70.doi: 10.2147/JPR.S85951
33. Lee SC, Klein-Schwartz W, Doyon S, Welsh C. Comparison of toxicity associated with nonmedical use of benzodiazepines with buprenorphine or methadone. *Drug and alcohol dependence*. 2014;138:118-23.doi:

34. Committee for Therapeutic Interventions and Evidence Based Practice. Guidance for the use of benzodiazepines in psychiatric practice. Royal Australian and New Zealand College of Psychiatrists; 2015.
35. Konopka A, Pełka Wysiecka J, Samochowiec J. Benzodiazepine misuse and addiction. Risk factors and adverse behavioral aspects. In: Preedy VR, editor. Neuropathology of Drug Addictions and Substance Misuse. San Diego: Academic Press; 2016. p. 327-33.
36. Zhu Y, Coyle DT, Mohamoud M, Zhou E, Eworuke E, Dormitzer C, et al. Concomitant use of buprenorphine for medication-assisted treatment of opioid use disorder and benzodiazepines: Using the prescription behavior surveillance system. *Drug Alcohol Depend.* 2018;187:221-6.doi: 10.1016/j.drugalcdep.2018.02.019
37. Insight Centre for AOD Training and Workforce Development. "Once a Drug User" - excerpt from Myths and Misconceptions surrounding substance use [cited 2021 9 Apr]. Available from: https://youtu.be/SPDYo_0-AKw.
38. Larney S, Zador D, Sindicich N, Dolan K. Patient experiences of opioid substitution therapy in prison: reasons for seeking and ceasing treatment. Sydney: Wiley-Blackwell; 2015 [cited 2021 15 Apr]. Available from: <https://ndarc.med.unsw.edu.au/resource/patient-motivations-perceptions-and-experiences-opioid-substitution-therapy-prison>.
39. Simon R, Snow R, Wakeman S. Understanding why patients with substance use disorders leave the hospital against medical advice: a qualitative study. *Substance abuse.* 2020;41(4):519-25.doi:
40. Moradinazar M, Farnia V, Alikhani M, Karyani AK, Rezaei S, Rezaeian S, et al. Factors related to relapse in patients with substance-related disorders under methadone maintenance therapy: decision tree analysis. *Oman medical journal.* 2020;35(1):e89.doi:
41. Shiraly R, Taghva M. Factors associated with sustained remission among chronic opioid users. *Addiction & health.* 2018;10(2):86-94.doi: 10.22122/ahj.v10i2.569
42. insight Centre for AOD Training and Workforce Development, QScript Learning. Considerations with a patient previously registered on QOTP - Dr Geraldine Chew [cited 2021 9 Apr]. Available from: <https://youtu.be/PROTmtKcO9A>.
43. Insight Centre for AOD Training and Workforce Development, QScript Learning. Management of previously registered QOTP patient - Dr Geraldine Chew [cited 2021 9 Apr]. Available from: <https://youtu.be/JQm0JCS8kM0>.
44. Monheit B, Pietrzak D, Hocking S. Prescription drug abuse- A timely update. *Australian Family Physician.* 2016;45(12):862-6.doi:
45. Cragg A, Hau JP, Woo SA, Kitchen SA, Liu C, Doyle-Waters MM, et al. Risk factors for misuse of prescribed opioids: a systematic review and meta-analysis. *Annals of emergency medicine.* 2019;74(5):634-46.doi:
46. Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and treatment of opioid misuse and addiction: a review. *JAMA psychiatry.* 2019;76(2):208-16.doi:
47. Guirguis A. Misuse of prescription and over-the-counter drugs to obtain illicit highs: How pharmacists can prevent abuse. *The Pharmaceutical Journal.* 2020;305(7943).doi:
48. Royal Australian College of General Practitioners. Prescribing drugs of dependence in general practice, Part B - benzodiazepines. Melbourne, VIC: RACGP; 2015 [cited 2019 Aug 1]. Available from: <https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/drugs-of-dependence>.
49. Insight Centre for AOD Training and Workforce Development, QScript Learning. Mastering the art of saying no - Unhappy role-play [cited 2021 9 Apr]. Available from: <https://youtu.be/ANvPULbGqw>.
50. insight Centre for AOD Training and Workforce Development, QScript Learning. Mastering the art of saying no - Happy role-play [cited 2021 9 Apr]. Available from: <https://youtu.be/RN04PP48Eps>.
51. Royal Australian College of General Practitioners. Prescribing drugs of dependence in general practice - Part C1: Opioids [cited 2019 Mar 21]. Available from: <https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/drugs-of-dependence>.
52. Dowell D, Haegerich TM, Chou R. CDC Guideline for prescribing opioids for chronic pain--United States, 2016. *JAMA.* 2016;315(15):1624-45.doi: 10.1001/jama.2016.1464
53. NPS MedicineWise. Risks of prescribing high-dose opioids: Information for health professionals [cited 2019 21 March]. Available from: <https://www.health.vic.gov.au/drugs-and-poisons/safer-use-of-opioids>.
54. Campbell G, Nielsen S, Bruno R, Lintzeris N, Cohen M, Hall W, et al. The Pain and Opioids IN Treatment study: characteristics of a cohort using opioids to manage chronic non-cancer pain. *Pain.* 2015;156(2):231-42.doi: 10.1097/01.j.pain.0000460303.63948.8e

55. Dassieu L, Kaboré J-L, Choinière M, Arruda N, Roy É. Chronic pain management among people who use drugs: A health policy challenge in the context of the opioid crisis. *International Journal of Drug Policy*. 2019;71:150-6.doi:
56. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafofomo C, et al. Long-term opioid management for chronic noncancer pain. *Cochrane Database of Systematic Reviews*. 2010(1).doi: 10.1002/14651858.CD006605.pub2
57. Faculty of Pain Medicine Australian and New Zealand College of Anaesthetists. Recommendations regarding the use of opioid analgesics in patients with chronic non-cancer pain [cited 2019 21 March]. Available from: <http://fpm.anzca.edu.au/documents/pm1-2010.pdf>.
58. Faculty of Pain Medicine ANZCA. PS01 (PM): Statement regarding the use of opioid analgesics in patients with chronic non-cancer pain [cited 2020 Jun 30]. Available from: <http://fpm.anzca.edu.au/resources/professional-documents>.
59. Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. *Pain Medicine*. 2016;17(1):85-98.doi: 10.1111/pme.12907
60. Michaelides A, Zis P. Depression, anxiety and acute pain: links and management challenges. *Postgraduate medicine*. 2019;131(7):438-44.doi:
61. Fountas A, Van Uum S, Karavitaki N. Opioid-induced endocrinopathies. *The Lancet Diabetes & Endocrinology*. 2020;8(1):68-80.doi:
62. Mercadante S, Arcuri E, Santoni A. Opioid-Induced Tolerance and Hyperalgesia. *CNS Drugs*. 2019;33(10):943-55.doi: 10.1007/s40263-019-00660-0
63. Insight Centre for AOD Training and Workforce Development, QScript Learning. Long term effects of opioids [cited 2021 9 Apr]. Available from: <https://youtu.be/qIBZtr9VOUk>.
64. Campbell G. Long-term opioid use in patients with chronic non-cancer pain [cited 2019 6 April]. Available from: <https://ndarc.med.unsw.edu.au/blog/long-term-opioid-use-patients-chronic-non-cancer-pain>.
65. Degenhardt L, Bruno R, Lintzeris N, Hall W, Nielsen S, Larance B, et al. Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): a cohort study. *Lancet Psychiatry*. 2015;2(4):314-22.doi:
66. Nielsen S, Lintzeris N, Bruno R, Campbell G, Larance B, Hall W, et al. Benzodiazepine use among chronic pain patients prescribed opioids: Associations with pain, physical and mental health, and health service utilization. *Pain Med*. 2015;16(2):356-66.doi: 10.1111/pme.12594
67. Dineen KK, DuBois JM. Between a rock and a hard place: Can physicians prescribe opioids to treat pain adequately while avoiding legal sanction? *Am J Law Med*. 2016;42(1):7-52.doi: 10.1177/0098858816644712
68. De Crescenzo F, Ciabattini M, D'Alo GL, De Giorgi R, Del Giovane C, Cassar C, et al. Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: A systematic review and network meta-analysis. *PLoS Med*. 2018;15(12):e1002715.doi: 10.1371/journal.pmed.1002715
69. Pergolizzi JV, Varrassi G, Paladini A, LeQuang J. Stopping or decreasing opioid therapy in patients on chronic opioid therapy. *Pain Ther*. 2019;8(2):163-76.doi: 10.1007/s40122-019-00135-6
70. Berna C, Kulich RJ, Rathmell JP. Tapering Long-term Opioid Therapy in Chronic Noncancer Pain. *Mayo Clinic Proceedings*. 2015;90(6):828-42.doi: 10.1016/j.mayocp.2015.04.003
71. James JR, Scott JM, Klein JW, Jackson S, McKinney C, Novack M, et al. Mortality after discontinuation of primary care-based chronic opioid therapy for pain: a retrospective cohort study. *Journal of General Internal Medicine*. 2019;34(12):2749-55.doi: 10.1007/s11606-019-05301-2
72. Mackey K, Anderson J, Bourne D, Chen E, Peterson K. VA Evidence-based synthesis program reports. Evidence Brief: Benefits and Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic Pain. Washington (DC): Department of Veterans Affairs (US); 2019.
73. Bedson J, Chen Y, Ashworth J, Hayward RA, Dunn KM, Jordan KP. Risk of adverse events in patients prescribed long-term opioids: A cohort study in the UK Clinical Practice Research Datalink. *European journal of pain (London, England)*. 2019;23(5):908-22.doi: 10.1002/ejp.1357
74. Boon M, van Dorp E, Broens S, Overdyk F. Combining opioids and benzodiazepines: effects on mortality and severe adverse respiratory events. *Annals of palliative medicine*. 2020;9(2):542-57.doi:
75. Islam MM, Wollersheim D. A comparison of opioids and benzodiazepines dispensing in Australia. *PLoS One*. 2019;14(8):e0221438-e.doi: 10.1371/journal.pone.0221438
76. Pino CA, Covington M, Wakeman SE. Prescription of opioids for acute pain in opioid naïve patients. *UpToDate*. 2020 [cited 2020 2 Apr]. Available from: <https://www.uptodate.com/contents/prescription-of-opioids-for-acute-pain-in-opioid-naive-patients>.

77. Shah A, Hayes CJ, Martin BC. Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use - United States, 2006-2015. *MMWR Morbidity and mortality weekly report*. 2017;66(10):265.doi: 10.15585/mmwr.mm6610a1
78. Morgan SG, Weymann D. Patterns, predictors and persistence of chronic sedative use: a population-based observational study of older adults in British Columbia, Canada. *European journal of clinical pharmacology*. 2017;73(8):1001.doi: 10.1007/s00228-017-2253-z
79. Gerlach LB, Maust DT, Leong SH, Mavandadi S, Oslin DW. Factors associated with long-term benzodiazepine use among older adults. *JAMA internal medicine*. 2018;178(11):1560-2.doi: 10.1001/jamainternmed.2018.2413
80. Johnson SP, Chung KC, Zhong L, Shauver MJ, Engelsbe MJ, Brummett C, et al. Risk of prolonged opioid use among opioid-naïve patients following common hand surgery procedures. *The Journal of hand surgery*. 2016;41(10):947-57.e3.doi: 10.1016/j.jhsa.2016.07.113
81. Lader M. Benzodiazepine harm: How can it be reduced? *British Journal of Clinical Pharmacology*. 2014;77(2):295-301.doi: 10.1111/j.1365-2125.2012.04418.x
82. Hallway A, Vu J, Lee J, Palazzolo W, Waljee J, Brummett C, et al. Patient Satisfaction and Pain Control Using an Opioid-Sparing Postoperative Pathway. *Journal of the American College of Surgeons*. 2019;229(3):316-22.doi: 10.1016/j.jamcollsurg.2019.04.020
83. Darnall BD, Ziadni MS, Stieg RL, Mackey IG, Kao M-C, Flood P. Patient-Centered Prescription Opioid Tapering in Community Outpatients With Chronic Pain. *JAMA internal medicine*. 2018;178(5):707-8.doi: 10.1001/jamainternmed.2017.8709
84. Insight Centre for AOD Training and Workforce Development. Withdrawal management quick reference guide - Opioids [cited 2019 27 June]. Available from: <https://insight.qld.edu.au/shop/withdrawal-management-quick-reference-guide-opioids>.
85. Insight Centre for AOD Training and Workforce Development. Understanding the spectrum of withdrawal - Dr Mark Daghish [cited 2019 2 May]. Available from: https://youtu.be/5uwQtXV_Y_s.
86. Weir K, Jansen J, Bonner C, McCaffery K, Naganathan V. Medicines conversation guide [cited 2020 7 Dec]. Available from: <https://ses.library.usyd.edu.au/handle/2123/18330>.
87. Riess H. Addiction, empathy, and opioid alternatives [cited 2019 25 July]. Available from: <https://www.medscape.com/viewarticle/861351>.
88. Royal Australian College of General Practitioners. Prescribing drugs of dependence in general practice, Part A – Clinical governance framework [cited 2019 Aug 1]. Available from: <https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/drugs-of-dependence>.
89. Insight Centre for AOD Training and Workforce Development, QScript Learning. B.R.A.N. [cited 2021 13 Apr]. Available from: <https://www.youtube.com/watch?v=tFhwXEhtSHU&feature=youtu.be>.
90. Pharmaceutical Society of Australia. Guidelines for comprehensive medication management reviews 2020 [cited 2023 31 Jan]. Available from: <https://my.psa.org.au/s/article/guidelines-for-comprehensive-mmr>.
91. Elliott E, Booth JC. Problems with medicine use in older Australians: A review of recent literature. *Journal of Pharmacy Practice and Research*. 2014;44(4):258-71.doi: 10.1002/jppr.1041
92. O'Brien MDC, Wand APF. A systematic review of the evidence for the efficacy of opioids for chronic non-cancer pain in community-dwelling older adults. *Age and Ageing*. 2020;49(2):175-83.doi: 10.1093/ageing/afz175
93. Taylor DM, Paton C, Kapur S. *The Maudsley prescribing guidelines in psychiatry*. 13th ed. West Sussex, England: Wiley Blackwell; 2018.
94. Reeve E, Ong M, Wu A, Jansen J, Petrovic M, Gnjjidic D. A systematic review of interventions to deprescribe benzodiazepines and other hypnotics among older people. *European Journal of Clinical Pharmacology*. 2017;73(8):927-35.doi: 10.1007/s00228-017-2257-8
95. Royal Australian College of General Practitioners. Prescribing drugs of dependence in general practice, Part C2: The role of opioids in pain management [cited 2019 Mar 21]. Available from: <https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/drugs-of-dependence>.
96. Baldwin DS, Aitchison K, Bateson A, Curran HV, Davies S, Leonards B, et al. Benzodiazepines: Risks and benefits. A reconsideration. *Journal of Psychopharmacology*. 2013;27(11):967-71.doi: 10.1177/0269881113503509
97. Gazelka HM, Leal JC, Lapid MI, Rummans TA. Opioids in Older Adults: Indications, Prescribing, Complications, and Alternative Therapies for Primary Care. *Mayo Clinic Proceedings*. 2020;95(4):793-800.doi: 10.1016/j.mayocp.2020.02.002

98. Ali A, Arif AW, Bhan C, Kumar D, Malik MB, Syyed Z, et al. Managing chronic pain in the elderly: an overview of the recent therapeutic advancements. *Cureus*. 2018;10(9):e3293-e.doi: 10.7759/cureus.3293
99. Bantel C, Hoffmann F, Jobski K. Pain And The Use Of Gabapentinoids In German Nursing Home Residents - Results From An Analysis Based On Statutory Health Insurance Data. *Journal of Pain Research*. 2019;12:3175-84.doi: 10.2147/JPR.S221579
100. Bettinger JJ, Wegrzyn EL, Fudin J. Pain Management in the Elderly: Focus on Safe Prescribing. *Practical Pain Management*. 2017; 17(3). Available from: <https://www.practicalpainmanagement.com/treatments/pharmacological/opioids/pain-management-elderly-focus-safe-prescribing>.
101. Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. *Therapeutic Advances in Drug Safety*. 2014;5(1):38-56.doi: 10.1177/2042098613505614
102. Fleet JL, Dixon SN, Kuwornu PJ, Dev VK, Montero-Odasso M, Burneo J, et al. Gabapentin dose and the 30-day risk of altered mental status in older adults: A retrospective population-based study. *PLoS One*. 2018;13(3):e0193134.doi: 10.1371/journal.pone.0193134
103. Ballóková AL, Fialová D. Benzodiazepines, age-related pharmacological changes, and risk of falls in older adults. In: Preedy VR, editor. *Neuropathology of Drug Addictions and Substance Misuse*. San Diego: Academic Press; 2016. p. 334-44.
104. Brkic J, Fialova D, Okuyan B, Kummer I, Sesto S, Capiou A, et al. Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta-analysis. *Scientific Reports*. 2022;12(1):16774.doi: 10.1038/s41598-022-01931-4
105. Markota M, Rummans TA, Bostwick JM, Lapid MI. Benzodiazepine use in older adults: dangers, management, and alternative therapies. *Mayo Clin Proc*. 2016;91(11):1632-9.doi: 10.1016/j.mayocp.2016.07.024
106. Brett J, Murnion B. Management of benzodiazepine misuse and dependence. *Australian Prescriber*. 2015;38(5):152-5.doi: 10.18773/austprescr.2015.055
107. El-Saifi N, Moyle W, Jones C, Tuffaha H. Quetiapine safety in older adults: a systematic literature review. *Journal of clinical pharmacy and therapeutics*. 2016;41(1):7-18.doi: 10.1111/jcpt.12357
108. Rochon PA. Drug prescribing for older adults. Available from: <https://www.uptodate.com/contents/drug-prescribing-for-older-adults>.
109. El Shamy T, Tamizian O. Principles of prescribing in pregnancy. *Obstetrics, Gynaecology and Reproductive Medicine*. 2018;28(5):136-40.doi: 10.1016/j.ogrm.2018.03.005
110. Ecker J, Abuhamad A, Hill W, Bailit J, Bateman BT, Berghella V, et al. Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine. *American Journal of Obstetrics & Gynecology*. 2019;221(1):B5-B28.doi: 10.1016/j.ajog.2018.11.005
111. Pagé MG, Kudrina I, Zomahoun HTV, Ziegler D, Beaulieu P, Charbonneau C, et al. Relative frequency and risk factors for long-term opioid therapy following surgery and trauma among adults: a systematic review protocol. *Systematic Reviews*. 2018;7(1):97.doi: 10.1186/s13643-018-0760-3
112. Kułak-Bejda A, Waszkiewicz N, Popławska R, Bejda G. The impact of high doses of pregabalin on pregnancy – case report. *Psychiatry and Clinical Psychopharmacology*. 2019;29(1):97-9.doi: 10.1080/24750573.2018.1505452
113. Ray-Griffith SL, Morrison B, Stowe ZN. Chronic pain prevalence and exposures during pregnancy. *Pain research & management*. 2019;2019:6985164.doi: 10.1155/2019/6985164
114. Zaghaw A, Koronfel M, Podgorski E, Siddiqui S, Valliani A, Karmakar A, et al. Pain Management for Pregnant Women in the Opioid Crisis Era. 2018. In: *Pain Management in Special Circumstances*. IntechOpen. Available from: <https://www.intechopen.com/books/pain-management-in-special-circumstances/pain-management-for-pregnant-women-in-the-opioid-crisis-era>.
115. Bellantuono C, Tofani S, Sciascio GD, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: A critical overview. *General Hospital Psychiatry*. 2013;35(1):3-8.doi: 10.1016/j.genhosppsych.2012.09.003
116. Manning V, Arunogiri S, Frei M, Ridley K, Mroz K, Campbell S, et al. Alcohol and other drug withdrawal guidelines. Richmond, Victoria: Turning Point; 2018 [cited 2019 27 June]. Available from: <https://www.turningpoint.org.au/sites/default/files/inline-files/Alcohol-and-Drug-Withdrawal-Guidelines-2018.pdf>.

117. Kieviet N, Dolman KM, Honig A. The use of psychotropic medication during pregnancy: How about the newborn? *Neuropsychiatric Disease and Treatment*. 2013;9:1257-66.doi: 10.2147/NDT.S36394
118. NSW Ministry of Health. Clinical guidelines: Substance use during pregnancy, birth and the postnatal period. NSW: NSW Ministry of Health; 2014 [cited 2019 14 March]. Available from: <https://www.health.nsw.gov.au/aod/professionals/Pages/substance-use-during-pregnancy-guidelines.aspx>.
119. Ferro A. Paediatric prescribing: Why children are not small adults. *British Journal of Clinical Pharmacology*. 2015;79(3):351-3.doi: 10.1111/bcp.12540
120. Analgesic Expert Group. Pain in Children [cited 2020 Apr 21]. Available from: <https://tgldcdp.tg.org.au/guideLine?guidelinePage=Analgesic&frompage=etgcomplete>.
121. Bell J, Paget SP, Nielsen TC, Buckley NA, Collins J, Pearson S-A, et al. Prescription opioid dispensing in Australian children and adolescents: a national population-based study. *The Lancet Child & Adolescent Health*. 2019;3(12):881-8.doi: 10.1016/S2352-4642(19)30329-3
122. Matson KL, Johnson PN, Tran V, Horton ER, Sterner-Allison J. Opioid use in children. *The Journal of Pediatric Pharmacology and Therapeutics*. 2019;24(1):72-5.doi: 10.5863/1551-6776-24.1.72
123. Cooper TE, Wiffen PJ, Heathcote LC, Clinch J, Howard R, Krane E, et al. Antiepileptic drugs for chronic non-cancer pain in children and adolescents. *Cochrane Database of Systematic Reviews*. 2017;8:CD012536.doi: 10.1002/14651858.CD012536.pub2
124. Egunsola O, Wylie CE, Chitty KM, Buckley NA. Systematic Review of the Efficacy and Safety of Gabapentin and Pregabalin for Pain in Children and Adolescents. *Anesthesia and analgesia*. 2019;128(4):811-9.doi: 10.1213/ane.0000000000003936
125. Psychotropic Expert Group. Disorders usually first diagnosed in childhood and adolescence [cited 2020 Apr 22]. Available from: <https://tgldcdp-tg-org-au/viewTopic?topicfile=psychiatric-disorders-children§ionId=ptg-c16-s4#ptg-c16-s4-4>.
126. Leonate KG, Puliafico A, Na P, Rynn MA. Pharmacotherapy for anxiety disorders in children and adolescents [cited 2020 Apr 21]. Available from: <https://www.uptodate.com/contents/pharmacotherapy-for-anxiety-disorders-in-children-and-adolescents>.
127. Catalá-López F, Hutton B, Núñez-Beltrán A, Page MJ, Ridao M, Macías Saint-Gerons D, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. *PLoS One*. 2017;12(7):e0180355-e.doi: 10.1371/journal.pone.0180355
128. Costello EJ, Maughan B. Annual research review: Optimal outcomes of child and adolescent mental illness. *J Child Psychol Psychiatry*. 2015;56(3):324-41.doi: 10.1111/jcpp.12371
129. The Royal Australian and New Zealand College of Psychiatrists. Guidance for psychotropic medication use in children and adolescents [cited 2020 Apr 22]. Available from: https://www.ranzcp.org/files/resources/college_statements/practice_guidelines/ppg7-guidance-for-psychotropic-medication-use-in-c.aspx.
130. Sinnott C, Mc Hugh S, Browne J, Bradley C. GPs' perspectives on the management of patients with multimorbidity: systematic review and synthesis of qualitative research. *BMJ Open*. 2013;3(9):e003610.doi: 10.1136/bmjopen-2013-003610
131. Kumar S. Burnout and doctors: prevalence, prevention and intervention. *Healthcare (Basel)*. 2016;4(3):37.doi: 10.3390/healthcare4030037
132. Unger J-P. Physicians' burnout (and that of psychologists, nurses, magistrates, researchers, and professors) for a control program. *International Journal of Health Services*. 2019;50(1):73-81.doi: 10.1177/0020731419883525
133. Insight Centre for AOD Training and Workforce Development, editor Micro-counselling and brief interventions. *Insight workshops*; 2020; Brisbane.